Breeze Holdings Acquisition Corp. shareholders voted to approve the business combination with YD Biopharma Limited.
The combined company will be named YD Bio Limited and is expected to trade on Nasdaq under the new ticker symbol YDES.
Closing of the transaction is expected in the next two weeks, subject to customary closing conditions.
Business Combination Approved
Stockholders voted overwhelmingly in favor of the business combination, setting the stage for YD Biopharma Limited's integration with Breeze Holdings Acquisition Corp.
New Ticker Symbol
Upon closing, the combined company will trade on Nasdaq under the ticker symbol YDES, reflecting the new identity as YD Bio Limited.
Advisors Involved
Legal advisors for YD Biopharma include ArentFox Schiff LLP, while financial advice for Breeze came from I-Bankers Securities, Inc. and legal advice from Woolery & Co. PLLC and Ogier.
- The approval of the business combination marks a significant step towards the integration of YD Biopharma's innovative vaccines and therapeutics into the public market through Breeze Holdings Acquisition Corp.
- The trading of YD Bio Limited under the new ticker symbol YDES on Nasdaq is expected to enhance visibility and accessibility for investors interested in biopharmaceutical companies.
The successful approval by shareholders and the upcoming trading as YD Bio Limited on Nasdaq signify promising developments for the future growth and visibility of YD Biopharma Limited.